**Core Concept**
Pneumocystis jirovecii (formerly known as Pneumocystis carinii) is an opportunistic fungal pathogen that causes Pneumocystis pneumonia (PCP) primarily in immunocompromised individuals, particularly those with HIV/AIDS. It involves the lungs, where it causes inflammation and damage to the alveoli, leading to difficulty breathing.

**Why the Correct Answer is Right**
P. jirovecii is a unique fungal pathogen that differs from other fungi in its biology and clinical manifestations. It is not a protozoan, despite initial classification as such. The pathogenesis of PCP involves the attachment of P. jirovecii to the alveolar epithelium, leading to the release of cystic forms that cause damage to the lung tissue. This results in the characteristic symptoms of PCP, including cough, shortness of breath, and fever.

**Why Each Wrong Option is Incorrect**
**Option A:** P. jirovecii is a protozoan. Incorrect because P. jirovecii is a fungus, not a protozoan.
**Option B:** PCP is typically seen in healthy individuals. Incorrect because PCP is primarily seen in immunocompromised individuals, particularly those with HIV/AIDS.
**Option C:** P. jirovecii is sensitive to sulfonamides. Incorrect because P. jirovecii is actually resistant to sulfonamides, and trimethoprim-sulfamethoxazole (TMP-SMX) is the preferred treatment for PCP.
**Option D:** PCP is characterized by the presence of eosinophils in the sputum. Incorrect because PCP is characterized by an increase in lymphocytes and macrophages in the sputum, not eosinophils.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that P. jirovecii is not a protozoan, and its diagnosis requires specific laboratory tests, such as PCR or microscopy of induced sputum.

**Correct Answer: C. P. jirovecii is sensitive to sulfonamides. Trimethoprim-sulfamethoxazole is the preferred treatment for PCP.**